BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents

Cancer Cell

Volumn 12, Issue 2, 2007, Pages 171-185

  Deng, Jing ^a   Carlson, Nicole ^a   Takeyama, Kunihiko ^a   Dal Cin, Paola ^b   Shipp, Margaret ^a   Letai, Anthony ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CELLCYCLE

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; DOXORUBICIN; ETOPOSIDE; PROTEIN BCL 2; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LYMPHOMA CELL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL;

EID: 34547603628     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.07.001     Document Type: Article

References (53)

1. Bakhshi A., Jensen J.P., Goldman P., Wright J.J., McBride O.W., Epstein A.L., and Korsmeyer S.J. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41 (1985) 899-906
2. Cartron P.F., Gallenne T., Bougras G., Gautier F., Manero F., Vusio P., Meflah K., Vallette F.M., and Juin P. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol. Cell 16 (2004) 807-818
3. Certo M., Moore Vdel G., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., and Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9 (2006) 351-365
4. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., and Huang D.C. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17 (2005) 393-403
5. Cheng E.H., Levine B., Boise L.H., Thompson C.B., and Hardwick J.M. Bax-independent inhibition of apoptosis by Bcl-XL. Nature 379 (1996) 554-556
6. Cheng E.H., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., and Korsmeyer S.J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8 (2001) 705-711
7. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., and Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
8. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 102 (2005) 13944-13949
9. Cleary M.L., and Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. USA 82 (1985) 7439-7443
10. Cory S., and Adams J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2 (2002) 647-656
11. Danial N.N., and Korsmeyer S.J. Cell death: Critical control points. Cell 116 (2004) 205-219
12. Decaudin D., Geley S., Hirsch T., Castedo M., Marchetti P., Macho A., Kofler R., and Kroemer G. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res. 57 (1997) 62-67
13. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., and Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 117 (2007) 112-121
14. Desagher S., Osen-Sand A., Nichols A., Eskes R., Montessuit S., Lauper S., Maundrell K., Antonsson B., and Martinou J.C. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol. 144 (1999) 891-901
15. Ernst P., Mabon M., Davidson A.J., Zon L.I., and Korsmeyer S.J. An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr. Biol. 14 (2004) 2063-2069
16. Gascoyne R.D., Adomat S.A., Krajewski S., Krajewska M., Horsman D.E., Tolcher A.W., O'Reilly S.E., Hoskins P., Coldman A.J., Reed J.C., and Connors J.M. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90 (1997) 244-251
17. Green D.R., and Evan G.I. A matter of life and death. Cancer Cell 1 (2002) 19-30
18. Green D.R., and Kroemer G. The pathophysiology of mitochondrial cell death. Science 305 (2004) 626-629
19. Gross A., McDonnell J.M., and Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13 (1999) 1899-1911
20. Hahn W.C., and Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2 (2002) 331-341
21. Hsu Y.T., and Youle R.J. Nonionic detergents induce dimerization among members of the Bcl-2 family. J. Biol. Chem. 272 (1997) 13829-13834
22. Hsu Y.T., Wolter K.G., and Youle R.J. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc. Natl. Acad. Sci. USA 94 (1997) 3668-3672
23. Huang D.C., and Strasser A. BH3-only proteins-Essential initiators of apoptotic cell death. Cell 103 (2000) 839-842
24. Iqbal J., Neppalli V.T., Wright G., Dave B.J., Horsman D.E., Rosenwald A., Lynch J., Hans C.P., Weisenburger D.D., Greiner T.C., et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J. Clin. Oncol. 24 (2006) 961-968
25. Karbowski M., Norris K.L., Cleland M.M., Jeong S.Y., and Youle R.J. Role of Bax and Bak in mitochondrial morphogenesis. Nature 443 (2006) 658-662
26. Kelekar A., Chang B.S., Harlan J.E., Fesik S.W., and Thompson C.B. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Mol. Cell. Biol. 17 (1997) 7040-7046
27. Kelekar A., and Thompson C.B. Bcl-2-family proteins: The role of the BH3 domain in apoptosis. Trends Cell Biol. 8 (1998) 324-330
28. Kim H., Rafiuddin-Shah M., Tu H.C., Jeffers J.R., Zambetti G.P., Hsieh J.J., and Cheng E.H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8 (2006) 1348-1358
29. Kojima H., Endo K., Moriyama H., Tanaka Y., Alnemri E.S., Slapak C.A., Teicher B., Kufe D., and Datta R. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J. Biol. Chem. 273 (1998) 16647-16650
30. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.X., Sneed T., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10 (2006) 375-388
31. Kramer M.H., Hermans J., Parker J., Krol A.D., Kluin-Nelemans J.C., Haak H.L., van Groningen K., van Krieken J.H., de Jong D., and Kluin P.M. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J. Clin. Oncol. 14 (1996) 2131-2138
32. Kuwana T., Mackey M.R., Perkins G., Ellisman M.H., Latterich M., Schneiter R., Green D.R., and Newmeyer D.D. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111 (2002) 331-342
33. Kuwana T., Bouchier-Hayes L., Chipuk J.E., Bonzon C., Sullivan B.A., Green D.R., and Newmeyer D.D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17 (2005) 525-535
34. Letai A. BH3 domains as BCL-2 inhibitors: Prototype cancer therapeutics. Expert Opin. Biol. Ther. 3 (2003) 293-304
35. Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J. Clin. Invest. 115 (2005) 2648-2655
36. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., and Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002) 183-192
37. Letai A., Beard C., Sorcinelli M., and Korsmeyer S.J. Anti-apoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6 (2004) 241-249
38. Lin X., Morgan-Lappe S., Huang X., Li L., Zakula D.M., Vernetti L.A., Fesik S.W., and Shen Y. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. Oncogene 26 (2006) 3972-3979
39. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
40. Marani M., Tenev T., Hancock D., Downward J., and Lemoine N.R. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol. Cell. Biol. 22 (2002) 3577-3589
41. Muchmore S.W., Sattler M., Liang H., Meadows R.P., Harlan J.E., Yoon H.S., Nettesheim D., Chang B.S., Thompson C.B., Wong S.L., et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381 (1996) 335-341
42. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
43. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., and Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426 (2003) 671-676
44. Sattler M., Liang H., Nettesheim D., Meadows R.P., Harlan J.E., Eberstadt M., Yoon H.S., Shuker S.B., Chang B.S., Minn A.J., et al. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 275 (1997) 983-986
45. Scorrano L., Oakes S.A., Opferman J.T., Cheng E.H., Sorcinelli M.D., Pozzan T., and Korsmeyer S.J. BAX and BAK regulation of endoplasmic reticulum Ca2+: A control point for apoptosis. Science 300 (2003) 135-139
46. Tsujimoto Y., Cossman J., Jaffe E., and Croce C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228 (1985) 1440-1443
47. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10 (2006) 389-399
48. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 15 (2001) 2922-2933
49. Wei M.C., Lindsten T., Mootha V.K., Weiler S., Gross A., Ashiya M., Thompson C.B., and Korsmeyer S.J. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14 (2000) 2060-2071
50. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., and Korsmeyer S.J. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
51. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., Ierino H., Lee E.F., Fairlie W.D., Bouillet P., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 (2007) 856-859
52. Zong W.X., Lindsten T., Ross A.J., MacGregor G.R., and Thompson C.B. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 15 (2001) 1481-1486
53. Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., and Thompson C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 18 (2004) 1272-1282